Vlad Ratziu - Concepedia

Author

Vlad Ratziu

Also Known As

Alnoor Ramji, Jenny Lee, Jerome Boursier, Joanne Verheij, P Rodrigues, Pierre Bedossa, Ratziu Vlad, Ratziu, V, Ratziu, V., Ratziu, Vlad

690

Publications

60.9K

Citations

107

H-Index

130

Concepts

All Affiliations

Sorbonne Université Pitié-Salpêtrière Hospital Assistance Publique – Hôpitaux de Paris Inserm Fondation pour l’innovation en Cadiométabolisme et Nutrition

About

Vlad Ratziu is an author at Sorbonne Université specializing in medicine, hepatology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	96	15.6K
2	Health Sciences	36	48	11.2K
3	Public Health	4	4	153
4	Engineering	2	2	115
5	Natural Sciences	2	2	47

Vlad Ratziu

233

Publications

41K

Citations

H-Index

Page 1

	Year	Citations
A multisociety Delphi consensus statement on new fatty liver disease nomenclature Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Hepatology Evidence-based MedicinePathologyFatty Liver DiseaseObesityMetabolic Syndrome	2023	2.5K
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease Vlad Ratziu, Frédéric Charlotte, A. Heurtier, Gastroenterology HepatologyNonalcoholic Fatty Liver DiseaseLiver PhysiologyHistopathologyDiagnosis	2005	2K
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 Chris Estes, Quentin M. Anstee, M. Arias, Journal of Hepatology	2018	1.9K
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, New England Journal of Medicine	2020	1.7K
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study Françoise Imbert‐Bismut, Vlad Ratziu, Laurence Piéroni, The Lancet Liver FibrosisBiochemical MarkersHepatologyHepatitis CViral Hepatitis	2001	1.4K
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy, New England Journal of Medicine	2024	1.4K
NASH limits anti-tumour surveillance in immunotherapy-treated HCC Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Nature	2021	1.2K
A position statement on NAFLD/NASH based on the EASL 2009 special conference Vlad Ratziu, Stefano Bellentani, Helena Cortez‐Pinto, Journal of Hepatology	2010	1.1K
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Vlad Ratziu, Stephen A. Harrison, Sven Francque, Gastroenterology	2016	993
Liver fibrosis in overweight patients Vlad Ratziu, Philippe Giral, Frédéric Charlotte, Gastroenterology ObesityMetabolic Associated SteatohepatitisBody CompositionHepatologyOverweight Patients	2000	969

Page 1